Astera Labs (NASDAQ:ALAB) Stock Price Down 1.9% – Time to Sell?

Astera Labs, Inc. (NASDAQ:ALAB) shares dropped 1.9% on Wednesday. The stock traded as low as $360.22 and last traded at $382.25. 4,990,725 shares were traded during trading, a decline of 4% from the average daily volume of 5,190,657 shares. The stock had previously closed at $389.80.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Fubon initiated coverage with a $500 price target, signaling meaningful upside potential from current levels and continued confidence in Astera Labs’ role in AI infrastructure connectivity. Fubon starts coverage with USD 500 target for Astera Labs stock
• Positive Sentiment: Recent enthusiasm around AI-related connectivity demand helped drive a sharp rally in ALAB, with coverage highlighting the stock’s strong year-to-date performance and investor interest in its data-center opportunity. ALAB Stock Jumps 7%—Why Astera Labs Is Rallying Today
• Neutral Sentiment: Astera Labs will report third-quarter 2026 financial results after the market closes on November 3, giving investors a near-term catalyst to evaluate demand, margins and forward guidance. Astera Labs Announces Conference Call to Review Third Quarter 2026 Financial Results
• Negative Sentiment: Zacks Research lowered its recommendation to “Hold,” citing the risk-reward balance after ALAB’s 118% year-to-date advance. Analysts also flagged its rich valuation, rising costs and increasing competition, including challenges from Marvell’s partnerships with Nvidia and Microsoft. Should You Buy, Sell, or Hold ALAB Stock After a 118% YTD Rise?

Analysts Set New Price Targets

Several equities research analysts have commented on ALAB shares. Needham & Company LLC boosted their price objective on Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Susquehanna boosted their price target on Astera Labs from $230.00 to $275.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Barclays raised their price objective on Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. UBS Group reaffirmed a “neutral” rating and set a $425.00 target price on shares of Astera Labs in a report on Wednesday, August 5th. Finally, Roth Capital reissued a “buy” rating and issued a $450.00 price target on shares of Astera Labs in a research note on Wednesday, August 5th. Twelve research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $348.33.

Astera Labs Stock Performance

The firm has a market capitalization of $66.32 billion, a price-to-earnings ratio of 189.23 and a beta of 3.68. The business has a 50 day simple moving average of $313.22 and a 200-day simple moving average of $286.60.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.11. The firm had revenue of $392.40 million for the quarter, compared to analysts’ expectations of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company’s revenue was up 104.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Equities analysts predict that Astera Labs, Inc. will post 2.7 earnings per share for the current fiscal year.

Insider Activity at Astera Labs

In other news, CEO Jitendra Mohan sold 90,630 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the completion of the sale, the chief executive officer owned 1,266,665 shares of the company’s stock, valued at $431,109,432.75. This represents a 6.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stefan A. Dyckerhoff sold 8,994 shares of Astera Labs stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.96, for a total transaction of $2,472,990.24. Following the sale, the director directly owned 3,309 shares in the company, valued at approximately $909,842.64. The trade was a 73.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 396,059 shares of company stock valued at $122,605,660 over the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Astera Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALAB. Greenleaf Trust grew its holdings in Astera Labs by 1.8% during the second quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock worth $966,000 after acquiring an additional 36 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Astera Labs by 74.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after purchasing an additional 41 shares in the last quarter. Glenmede Trust Co. NA boosted its position in shares of Astera Labs by 2.7% during the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after purchasing an additional 51 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Astera Labs during the 2nd quarter worth $25,000. Finally, Integrated Wealth Concepts LLC increased its holdings in shares of Astera Labs by 0.7% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,006 shares of the company’s stock valued at $3,384,000 after purchasing an additional 52 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

About Astera Labs

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data centers connect and manage processors, memory, storage, and networking components in high-performance computing systems.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) smart memory controllers, Scorpio PCIe switches, Taurus Ethernet fabric switches, and Leo CXL memory connectivity products.